Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab

Monoclonal antibodies targeting PD-1/PD-L1 signaling pathway have achieved unprecedented success in cancer treatment over the last few years. Atezolizumab is the first PD-L1 monoclonal antibody approved by US FDA for cancer therapy; however the molecular basis of atezolizumab in blocking PD-1/PD-L1...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Zhang, Fei, Qi, Xiaoqiang, Wang, Xiaoxiao, Wei, Diyang, Wu, Jiawei, Feng, Lingling, Cai, Haiyan, Wang, Yugang, Zeng, Naiyan, Xu, Ting, Zhou, Aiwu, Zheng, Ying
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2017
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5685743/
https://ncbi.nlm.nih.gov/pubmed/29163822
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.21652
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires